[The prognostic importance of urinase type plasminogen activators (uPA) and plasminogen activator inhibitors (PAI-1) in the primary resection of oral squamous cell carcinoma]
- PMID: 15138855
- DOI: 10.1007/s10006-003-0520-x
[The prognostic importance of urinase type plasminogen activators (uPA) and plasminogen activator inhibitors (PAI-1) in the primary resection of oral squamous cell carcinoma]
Abstract
This article examines the prognostic importance of urinase type plasminogen activators (uPA) and of plasminogen activator inhibitors (PAI-1) in cases of primary oral squamous cell carcinoma. Tissue samples were taken from the core of the tumour in 58 such primary surgical patients. The levels of uPA and PAI-1 were determined using ELISA. Statistical significance was calculated using the chi2- and log-rank tests. The mean follow-up (n=58) was 23 months. In order to determine prognostic value, the time before relapse was used. The mean time before relapse was 19 months. A total of 28 (40%) patients relapsed (local n=13, lymph node n=3, local and lymph node n=1, lymph node and skin n=1, other locations n=5). Such patients had significantly raised uPA (P<0.012) and PAI-1 (P<0.014) levels in the primary tumour. A optimal cutoff value for uPA (4.58 ng/mg) and PAI-1 (106.3 ng/mg) was determined using the multiple log-rank test. There was no significant correlation for patients with low or high levels (i.e. lower or higher than the cutoff value, respectively) with the usual clinical parameters such as localisation, N-stage, T-stage, differentiation and residual tumor status. Older patients (>58 years) had significantly higher levels of uPA and PAI-1 (P<0.017 and P<0.02, respectively). The likelihood of relapse was significantly higher in patients with high levels (uPA P<0.009, PAI-1 P<0.008). If the patients were divided into three groups depending on uPA and PAI-1 levels (group 1: uPA and PAI-1 low, n=35; group 2: uPA or PAI-1 high, n=12; group 3: uPA and PAI-1 high, n=11), relapses were more common in group 3 than in groups 1 or 2 (P<0.023). Patients with only surgical therapy (n=29) and those with postoperative radiotherapy (n=29) were used to evaluate postoperative follow-up. Cutoff levels were calculated for both groups. In the surgical therapy group this was uPA=5.63 ng/mg and PAI-1=106.3 ng/ml and in the surgical therapy plus radiotherapy group uPA=4.13 ng/mg and PAI-1=97.02 ng/mg. Kaplan-Meier curves showed a marked tendency for patients with higher levels to relapse more often. This is significant for surgical patients for PAI-1 (P<0.01) and for radiotherapy patients for uPA (P<0.04)
Similar articles
-
[Comparison of urokinase type plasminogen activators (uPA) and plasminogen activator inhibitors (PAI-1) in primary resection of oral squamous cell carcinoma].Mund Kiefer Gesichtschir. 2004 May;8(3):180-90. doi: 10.1007/s10006-003-0519-3. Epub 2004 Feb 6. Mund Kiefer Gesichtschir. 2004. PMID: 15138856 German.
-
Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity - clinical relevance and prognostic value.J Craniomaxillofac Surg. 2005 Jun;33(3):191-6. doi: 10.1016/j.jcms.2004.12.005. Epub 2005 Apr 22. J Craniomaxillofac Surg. 2005. PMID: 15878520
-
[Expression and significance of the urokinase-type plasminogen activator and its inhibitors in squamous cell carcinoma of human larynx].Zhonghua Er Bi Yan Hou Ke Za Zhi. 2003 Feb;38(1):39-42. Zhonghua Er Bi Yan Hou Ke Za Zhi. 2003. PMID: 12778766 Chinese.
-
Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer.Clin Breast Cancer. 2004 Dec;5(5):348-52. doi: 10.3816/cbc.2004.n.040. Clin Breast Cancer. 2004. PMID: 15585071 Review.
-
Clinical relevance of prognostic factors in axillary node-negative breast cancer.Onkologie. 2003 Oct;26(5):438-45. doi: 10.1159/000072976. Onkologie. 2003. PMID: 14605459 Review.
Cited by
-
SERPINE1 expression discriminates site-specific metastasis in human melanoma.Exp Dermatol. 2012 Jul;21(7):551-4. doi: 10.1111/j.1600-0625.2012.01523.x. Exp Dermatol. 2012. PMID: 22716255 Free PMC article.
-
PAI-1: An Integrator of Cell Signaling and Migration.Int J Cell Biol. 2011;2011:562481. doi: 10.1155/2011/562481. Epub 2011 Aug 3. Int J Cell Biol. 2011. PMID: 21837240 Free PMC article.
-
PAI-1 is a Critical Upstream Regulator of the TGF-beta1/EGF-Induced Invasive Phenotype in Mutant p53 Human Cutaneous Squamous Cell Carcinoma.J Biomed Biotechnol. 2007;2007(2):85208. doi: 10.1155/2007/85208. Epub 2007 Mar 20. J Biomed Biotechnol. 2007. PMID: 17515947 Free PMC article.
-
Transcriptome analysis of sinensetin-treated liver cancer cells guided by biological network analysis.Oncol Lett. 2021 May;21(5):355. doi: 10.3892/ol.2021.12616. Epub 2021 Mar 4. Oncol Lett. 2021. PMID: 33747212 Free PMC article.
-
PAI-1 Regulates the Invasive Phenotype in Human Cutaneous Squamous Cell Carcinoma.J Oncol. 2009;2009:963209. doi: 10.1155/2009/963209. Epub 2010 Mar 1. J Oncol. 2009. PMID: 20204159 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous